The new indirubin derivative inhibitors of glycogen synthase kinase-3, 6-BIDECO and 6-BIMYEO, prevent tau phosphorylation and apoptosis induced by the inhibition of protein phosphatase-2A by okadaic acid in cultured neurons

Journal of Neuroscience Research

Volumn 89, Issue 11, 2011, Pages 1802-1811

  Martin, Ludovic ^a   Magnaudeix, Amandine ^a   Wilson, Cornelia M ^a,b   Yardin, Catherine ^a,b   Terro, Faraj ^a,b  

^a UNIVERSITÉ DE LIMOGES   (France)

^b Hopital de la Mere et de l'Enfant   (France)

Author keywords

GSK3; Indirubins; Neuronal cell death; Neuroprotection; PP2A

Indexed keywords

6 BROMOINDIRUBIN 3' [O (2 MORPHOLIN 1 YLETHYL)OXIME]; 6 BROMOINDIRUBIN 3' [O (N,N DIETHYLCARBAMYL)OXIME]; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 5; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; INDIRUBIN; OKADAIC ACID; PHOSPHOPROTEIN PHOSPHATASE 2A; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BRAIN CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME INHIBITION; IC 50; IN VITRO STUDY; NERVE CELL CULTURE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; CELLS, CULTURED; CEREBRAL CORTEX; ENZYME INHIBITORS; GLYCOGEN SYNTHASE KINASE 3; INDOLES; NEURONS; OKADAIC ACID; OXIMES; PHOSPHORYLATION; PROTEIN PHOSPHATASE 2; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION; TAU PROTEINS;

EID: 80052634341     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.22723     Document Type: Article

References (48)

1. Abraha A, Ghoshal N, Gamblin TC, Cryns V, Berry RW, Kuret J, Binder LI. 2000. C-terminal inhibition of tau assembly in vitro and in Alzheimer's disease. J Cell Sci 113: 3737-3745.
2. Azorsa DO, Robeson RH, Frost D, Meec hoovet B, Brautigam GR, Dickey C, Beaudry C, Basu GD, Holz DR, Hernandez JA, Bisanz KM, Gwinn L, Grover A, Rogers J, Reiman EM, Hutton M, Stephan DA, Mousses S, Dunckley T. 2010. High-content siRNA screening of the kinome identifies kinases involved in Alzheimer's disease-related tau hyperphosphorylation. BMC Genomics 11: 25.
3. Braak H, Braak E. 1995. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging 16: 271-278; discussion278-284.
4. Chen S, Li B, Grundke-Iqbal I, Iqbal K. 2008. I1PP2A affects tau phosphorylation via association with the catalytic subunit of protein phosphatase 2A. J Biol Chem 283: 10513-10521.
5. Dickey CA, Kamal A, Lundgren K, Klosak N, Bailey RM, Dunmore J, Ash P, Shoraka S, Zlatkovic J, Eckman CB, Patterson C, Dickson DW, Nahman NSJr, Hutton M, Burrows F, Petrucelli L. 2007. The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. J Clin Invest 117: 648-658.
6. Ding Y, Qiao A, Fan GH. 2010. Indirubin-3'-monoxime rescues spatial memory deficits and attenuates beta-amyloid-associated neuropathology in a mouse model of Alzheimer's disease. Neurobiol Dis 39: 156-168.
7. Fath T, Eidenmuller J, Brandt R. 2002. Tau-mediated cytotoxicity in a pseudohyperphosphorylation model of Alzheimer's disease. J Neurosci 22: 9733-9741.
8. Fischer D, Mukrasch MD, Biernat J, Bibow S, Blackledge M, Griesinger C, Mandelkow E, Zweckstetter M. 2009. Conformational changes specific for pseudophosphorylation at serine 262 selectively impair binding of tau to microtubules. Biochemistry 48: 10047-10055.
9. Garcia A, Cayla X, Guergnon J, Dessauge F, Hospital V, Rebollo MP, Fleischer A, Rebollo A. 2003. Serine/threonine protein phosphatases PP1 and PP2A are key players in apoptosis. Biochimie 85: 721-726.
10. Gehringer MM. 2004. Microcystin-LR and okadaic acid-induced cellular effects: a dualistic response. FEBS Lett 557: 1-8.
11. Goedert M, Spillantini MG, Jakes R, Rutherford D, Crowther RA. 1989. Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron 3: 519-526.
12. Gong CX, Iqbal K. 2008. Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease. Curr Med Chem 15: 2321-2328.
13. Gong CX, Shaikh S, Wang JZ, Zaidi T, Grundke-Iqbal I, Iqbal K. 1995. Phosphatase activity toward abnormally phosphorylated tau: decrease in Alzheimer disease brain. J Neurochem 65: 732-738.
14. Haase C, Stieler JT, Arendt T, Holzer M. 2004. Pseudophosphorylation of tau protein alters its ability for self-aggregation. J Neurochem 88: 1509-1520.
15. Hanger DP, Anderton BH, Noble W. 2009. Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends Mol Med 15: 112-119.
16. Hu S, Begum AN, Jones MR, Oh MS, Beech WK, Beech BH, Yang F, Chen P, Ubeda OJ, Kim PC, Davies P, Ma Q, Cole GM, Frautschy SA. 2009. GSK3 inhibitors show benefits in an Alzheimer's disease (AD) model of neurodegeneration but adverse effects in control animals. Neurobiol Dis 33: 193-206.
17. Iqbal K, Grundke-Iqbal I. 1991. Ubiquitination and abnormal phosphorylation of paired helical filaments in Alzheimer's disease. Mol Neurobiol 5: 399-410.
18. Iqbal K, Liu F, Gong CX, Alonso Adel C, Grundke-Iqbal I. 2009. Mechanisms of tau-induced neurodegeneration. Acta Neuropathol 118: 53-69.
19. Janssens V, Longin S, Goris J. 2008. PP2A holoenzyme assembly: in cauda venenum (the sting is in the tail). Trends Biochem Sci 33: 113-121.
20. Jeganathan S, Hascher A, Chinnathambi S, Biernat J, Mandelkow EM, Mandelkow E. 2008. Proline-directed pseudo-phosphorylation at AT8 and PHF1 epitopes induces a compaction of the paperclip folding of tau and generates a pathological (MC-1) conformation. J Biol Chem 283: 32066-32076.
21. Kockeritz L, Doble B, Patel S, Woodgett JR. 2006. Glycogen synthase kinase-3-an overview of an overachieving protein kinase. Curr Drug Targets 7: 1377-1388.
22. Kosuga S, Tashiro E, Kajioka T, Ueki M, Shimizu Y, Imoto M. 2005. GSK-3beta directly phosphorylates and activates MARK2/PAR-1. J Biol Chem 280: 42715-42722.
23. Kroemer G, Galluzzi L, Vandenabeele P, Abrams J, Alnemri ES, Baehrecke EH, Blagosklonny MV, El-Deiry WS, Golstein P, Green DR, Hengartner M, Knight RA, Kumar S, Lipton SA, Malorni W, Nunez G, Peter ME, Tschopp J, Yuan J, Piacentini M, Zhivotovsky B, Melino G. 2009. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ 16: 3-11.
24. Lim YW, Yoon SY, Choi JE, Kim SM, Lee HS, Choe H, Lee SC, Kim DH. 2010. Maintained activity of glycogen synthase kinase-3beta despite of its phosphorylation at serine-9 in okadaic acid-induced neurodegenerative model. Biochem Biophys Res Commun 395: 207-212.
25. Lin CF, Chen CL, Chiang CW, Jan MS, Huang WC, Lin YS. 2007. GSK-3beta acts downstream of PP2A and the PI 3-kinase-Akt pathway, and upstream of caspase-2 in ceramide-induced mitochondrial apoptosis. J Cell Sci 120: 2935-2943.
26. Lindwall G, Cole RD. 1984. Phosphorylation affects the ability of tau protein to promote microtubule assembly. J Biol Chem 259: 5301-5305.
27. Liu F, Grundke-Iqbal I, Iqbal K, Gong CX. 2005. Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur J Neurosci 22: 1942-1950.
28. Liu F, Li B, Tung EJ, Grundke-Iqbal I, Iqbal K, Gong CX. 2007. Site-specific effects of tau phosphorylation on its microtubule assembly activity and self-aggregation. Eur J Neurosci 26: 3429-3436.
29. Liu GP, Zhang Y, Yao XQ, Zhang CE, Fang J, Wang Q, Wang JZ. 2008. Activation of glycogen synthase kinase-3 inhibits protein phosphatase-2A and the underlying mechanisms. Neurobiol Aging 29: 1348-1358.
30. Martin L, Magnaudeix A, Esclaire F, Yardin C, Terro F. 2009. Inhibition of glycogen synthase kinase-3beta downregulates total tau proteins in cultured neurons and its reversal by the blockade of protein phosphatase-2A. Brain Res 1252: 66-75.
31. Martin L, Latypova X, Terro F. 2011a. Post-translational modifications of tau protein: implications for Alzheimer's disease. Neurochem Int 58: 458-471.
32. Martin L, Page G, Terro F. 2011b. Tau phosphorylation and neuronal apoptosis induced by the blockade of PP2A preferentially involve GSK3β. Neurochem Int. In press, doi:10.1016/j.neuint.2011.05.010.
33. Meske V, Albert F, Ohm TG. 2008. Coupling of mammalian target of rapamycin with phosphoinositide 3-kinase signaling pathway regulates protein phosphatase 2A- and glycogen synthase kinase-3-dependent phosphorylation of tau. J Biol Chem 283: 100-109.
34. Pei JJ, Braak E, Braak H, Grundke-Iqbal I, Iqbal K, Winblad B, Cowburn RF. 1999. Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes. J Neuropathol Exp Neurol 58: 1010-1019.
35. Qian W, Shi J, Yin X, Iqbal K, Grundke-Iqbal I, Gong CX, Liu F. 2010. PP2A regulates tau phosphorylation directly and also indirectly via activating GSK-3beta. J Alzheimers Dis 19: 1221-1229.
36. Ryoo SR, Jeong HK, Radnaabazar C, Yoo JJ, Cho HJ, Lee HW, Kim IS, Cheon YH, Ahn YS, Chung SH, Song WJ. 2007. DYRK1A-mediated hyperphosphorylation of tau. A functional link between Down syndrome and Alzheimer disease. J Biol Chem 282: 34850-34857.
37. Selenica ML, Jensen HS, Larsen AK, Pedersen ML, Helboe L, Leist M, Lotharius J. 2007. Efficacy of small-molecule glycogen synthase kinase-3 inhibitors in the postnatal rat model of tau hyperphosphorylation. Br J Pharmacol 152: 959-979.
38. Sengupta A, Kabat J, Novak M, Wu Q, Grundke-Iqbal I, Iqbal K. 1998. Phosphorylation of tau at both Thr 231 and Ser 262 is required for maximal inhibition of its binding to microtubules. Arch Biochem Biophys 357: 299-309.
39. Seubert P, Mawal-Dewan M, Barbour R, Jakes R, Goedert M, Johnson GV, Litersky JM, Schenk D, Lieberburg I, Trojanowski JQ, et al. 1995. Detection of phosphorylated Ser262 in fetal tau, adult tau, and paired helical filament tau. J Biol Chem 270: 18917-18922.
40. Tanimukai H, Grundke-Iqbal I, Iqbal K. 2005. Up-regulation of inhibitors of protein phosphatase-2A in Alzheimer's disease. Am J Pathol 166: 1761-1771.
41. Van Hoof C, Goris J. 2003. Phosphatases in apoptosis: to be or not to be, PP2A is in the heart of the question. Biochim Biophys Acta 1640: 97-104.
42. Vougogiannopoulou K, Ferandin Y, Bettayeb K, Myrianthopoulos V, Lozach O, Fan Y, Johnson CH, Magiatis P, Skaltsounis AL, Mikros E, Meijer L. 2008. Soluble 3', 6-substituted indirubins with enhanced selectivity toward glycogen synthase kinase-3 alter circadian period. J Med Chem 51: 6421-6431.
43. Wang Y, Zhang JX, Du XX, Zhao L, Tian Q, Zhu LQ, Wang SH, Wang JZ. 2008. Temporal correlation of the memory deficit with Alzheimer-like lesions induced by activation of glycogen synthase kinase-3. J Neurochem 106: 2364-2374.
44. Woodgett JR. 1990. Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J 9: 2431-2438.
45. Xu Y, Chen Y, Zhang P, Jeffrey PD, Shi Y. 2008. Structure of a protein phosphatase 2A holoenzyme: insights into B55-mediated tau dephosphorylation. Mol Cell 31: 873-885.
46. Zhang Z, Simpkins JW. 2010a. An okadaic acid-induced model of tauopathy and cognitive deficiency. Brain Res 1359: 233-246.
47. Zhang Z, Simpkins JW. 2010b. Okadaic acid induces tau phosphorylation in SH-SY5Y cells in an estrogen-preventable manner. Brain Res 1345: 176-181.
48. Zhou XZ, Kops O, Werner A, Lu PJ, Shen M, Stoller G, Kullertz G, Stark M, Fischer G, Lu KP. 2000. Pin1-dependent prolyl isomerization regulates dephosphorylation of Cdc25C and tau proteins. Mol Cell 6: 873-883.